182 related articles for article (PubMed ID: 27909306)
21. Rearrangement of the AML1/CBFA2 gene in myeloid leukemia with the 3;21 translocation: expression of co-existing multiple chimeric genes with similar functions as transcriptional repressors, but with opposite tumorigenic properties.
Zent C; Kim N; Hiebert S; Zhang DE; Tenen DG; Rowley JD; Nucifora G
Curr Top Microbiol Immunol; 1996; 211():243-52. PubMed ID: 8585955
[TBL] [Abstract][Full Text] [Related]
22. Bortezomib therapy response is independent of cytogenetic abnormalities in relapsed/refractory multiple myeloma.
Chang H; Trieu Y; Qi X; Xu W; Stewart KA; Reece D
Leuk Res; 2007 Jun; 31(6):779-82. PubMed ID: 16996589
[TBL] [Abstract][Full Text] [Related]
23. Monosomy 13 in metaphase spreads is a predictor of poor long-term outcome after bortezomib plus dexamethasone treatment for relapsed/refractory multiple myeloma.
Kiyota M; Kobayashi T; Fuchida S; Yamamoto-Sugitani M; Ohshiro M; Shimura Y; Mizutani S; Nagoshi H; Sasaki N; Nakayama R; Chinen Y; Sakamoto N; Uchiyama H; Matsumoto Y; Horiike S; Shimazaki C; Kuroda J; Taniwaki M
Int J Hematol; 2012 May; 95(5):516-26. PubMed ID: 22426624
[TBL] [Abstract][Full Text] [Related]
24. Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p.
Neben K; Lokhorst HM; Jauch A; Bertsch U; Hielscher T; van der Holt B; Salwender H; Blau IW; Weisel K; Pfreundschuh M; Scheid C; Dührsen U; Lindemann W; Schmidt-Wolf IG; Peter N; Teschendorf C; Martin H; Haenel M; Derigs HG; Raab MS; Ho AD; van de Velde H; Hose D; Sonneveld P; Goldschmidt H
Blood; 2012 Jan; 119(4):940-8. PubMed ID: 22160383
[TBL] [Abstract][Full Text] [Related]
25. Predicting treatment benefit in multiple myeloma through simulation of alternative treatment effects.
Ubels J; Sonneveld P; van Beers EH; Broijl A; van Vliet MH; de Ridder J
Nat Commun; 2018 Jul; 9(1):2943. PubMed ID: 30054467
[TBL] [Abstract][Full Text] [Related]
26. Expression and prognostic significance of different mRNA 5'-end variants of the oncogene EVI1 in 266 patients with de novo AML: EVI1 and MDS1/EVI1 overexpression both predict short remission duration.
Haas K; Kundi M; Sperr WR; Esterbauer H; Ludwig WD; Ratei R; Koller E; Gruener H; Sauerland C; Fonatsch C; Valent P; Wieser R
Genes Chromosomes Cancer; 2008 Apr; 47(4):288-98. PubMed ID: 18181178
[TBL] [Abstract][Full Text] [Related]
27. Diamond-Blackfan anemia caused by chromosome 1p22 deletion encompassing
Tominaga M; Hamanoue S; Goto H; Saito T; Nagai JI; Masuno M; Umeda Y; Kurosawa K
Hum Genome Var; 2019; 6():36. PubMed ID: 31645974
[TBL] [Abstract][Full Text] [Related]
28. Ecotropic viral integration site 1, a novel oncogene in prostate cancer.
Queisser A; Hagedorn S; Wang H; Schaefer T; Konantz M; Alavi S; Deng M; Vogel W; von Mässenhausen A; Kristiansen G; Duensing S; Kirfel J; Lengerke C; Perner S
Oncogene; 2017 Mar; 36(11):1573-1584. PubMed ID: 27617580
[TBL] [Abstract][Full Text] [Related]
29. High EVI1 levels predict adverse outcome in acute myeloid leukemia: prevalence of EVI1 overexpression and chromosome 3q26 abnormalities underestimated.
Lugthart S; van Drunen E; van Norden Y; van Hoven A; Erpelinck CA; Valk PJ; Beverloo HB; Löwenberg B; Delwel R
Blood; 2008 Apr; 111(8):4329-37. PubMed ID: 18272813
[TBL] [Abstract][Full Text] [Related]
30. [Prognostic value of 1q21 amplification in multiple myeloma].
Abramova TV; Obukhova TN; Mendeleeva LP; Pokrovskaya OS; Gribanova EO; Ryzhko VV; Grebenyuk LA; Nareyko MV; Solovyev MV; Votyakova OM; Kulikov SM; Rusinov MA; Savchenko VG
Ter Arkh; 2017; 89(7):32-38. PubMed ID: 28766538
[TBL] [Abstract][Full Text] [Related]
31. Bortezomib, thalidomide, dexamethasone, and panobinostat for patients with relapsed multiple myeloma (MUK-six): a multicentre, open-label, phase 1/2 trial.
Popat R; Brown SR; Flanagan L; Hall A; Gregory W; Kishore B; Streetly M; Oakervee H; Yong K; Cook G; Low E; Cavenagh J;
Lancet Haematol; 2016 Dec; 3(12):e572-e580. PubMed ID: 27843120
[TBL] [Abstract][Full Text] [Related]
32. Drug response prediction in high-risk multiple myeloma.
Vangsted AJ; Helm-Petersen S; Cowland JB; Jensen PB; Gimsing P; Barlogie B; Knudsen S
Gene; 2018 Feb; 644():80-86. PubMed ID: 29122646
[TBL] [Abstract][Full Text] [Related]
33. MTDH is an oncogene in multiple myeloma, which is suppressed by Bortezomib treatment.
Gu C; Feng L; Peng H; Yang H; Feng Z; Yang Y
Oncotarget; 2016 Jan; 7(4):4559-69. PubMed ID: 26683226
[TBL] [Abstract][Full Text] [Related]
34. Identification of two critically deleted regions within chromosome segment 7q35-q36 in EVI1 deregulated myeloid leukemia cell lines.
De Weer A; Poppe B; Vergult S; Van Vlierberghe P; Petrick M; De Bock R; Benoit Y; Noens L; De Paepe A; Van Roy N; Menten B; Speleman F
PLoS One; 2010 Jan; 5(1):e8676. PubMed ID: 20084277
[TBL] [Abstract][Full Text] [Related]
35. Chromosome 1q21 gains confer inferior outcomes in multiple myeloma treated with bortezomib but copy number variation and percentage of plasma cells involved have no additional prognostic value.
An G; Xu Y; Shi L; Shizhen Z; Deng S; Xie Z; Sui W; Zhan F; Qiu L
Haematologica; 2014 Feb; 99(2):353-9. PubMed ID: 24213147
[TBL] [Abstract][Full Text] [Related]
36. Low frequency mutations in ribosomal proteins RPL10 and RPL5 in multiple myeloma.
Hofman IJF; Patchett S; van Duin M; Geerdens E; Verbeeck J; Michaux L; Delforge M; Sonneveld P; Johnson AW; De Keersmaecker K
Haematologica; 2017 Aug; 102(8):e317-e320. PubMed ID: 28428269
[No Abstract] [Full Text] [Related]
37. [Intracranial involvement in newly diagnosed multiple myeloma with TP53 deletion: Two case reports].
Qu S; Liao L; Xie Y; Zheng Z; Chen B
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2018 Nov; 43(11):1272-1275. PubMed ID: 30643076
[TBL] [Abstract][Full Text] [Related]
38. [Effect of 1q21 amplification on bortezomib therapeutic response and prognosis of newly diagnosed multiple myeloma patients].
Liu XL; Yang PY; Yu XY; Chen JC; Liu XL; Bai J; Liu YM; He H; Sun JN; Fan HQ; Zhang C; Zhang Y; Su KJ; Liu CS; Tan YH; Gao SJ; Li W; Jin FY
Zhonghua Xue Ye Xue Za Zhi; 2018 May; 39(5):408-413. PubMed ID: 29779352
[No Abstract] [Full Text] [Related]
39. Bortezomib and Thalidomide Treatment Results in Newly Diagnosed Transplant-Ineligible Multiple Myeloma Patients are Comparable in Long-Term Follow-Up.
Stork M; Sandecká V; Boichuk I; Adam Z; Krejci M; Brozova L; Sevcikova S; Pour L
Klin Onkol; 2019; 32(6):445-452. PubMed ID: 31842563
[TBL] [Abstract][Full Text] [Related]
40. Panobinostat for the Treatment of Multiple Myeloma.
Laubach JP; Moreau P; San-Miguel JF; Richardson PG
Clin Cancer Res; 2015 Nov; 21(21):4767-73. PubMed ID: 26362997
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]